mirabegron + solifenacin
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Overactive Bladder
Conditions
Overactive Bladder
Trial Timeline
Oct 1, 2012 โ Jul 23, 2013
NCT ID
NCT01745094About mirabegron + solifenacin
mirabegron + solifenacin is a approved stage product being developed by Astellas Pharma for Overactive Bladder. The current trial status is completed. This product is registered under clinical trial identifier NCT01745094. Target conditions include Overactive Bladder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01745094 | Approved | Completed |
Competing Products
20 competing products in Overactive Bladder